S23-196 Pioneering Targeted Gene Therapy for Treatment of Glaucoma and Inner Retinal Disorders Stanford researchers have developed a pioneering gene therapy by targeting reactive astrocytes in the optic nerve head (ONH) and modulating cyclic adenosine monophosphate (cAMP) levels for targeted treatment of glaucoma and other retinal disorders. Jeffrey Goldberg Evan Cameron Anna Toth